Published in Int J Neurosci on October 31, 2013
Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm (2015) 1.15
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Aquaporin-4-positive myelitis associated with Sjögren syndrome and colonic adenocarcinoma. Neurol Neuroimmunol Neuroinflamm (2015) 0.75
Screening for onconeural antibodies in neuromyelitis optica spectrum disorders. BMC Neurol (2017) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 1.59
Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler (2008) 1.55
A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurol Sci (2009) 1.12
Devic disease and thymoma with anti-central nervous system and antithymus antibodies. Neurology (2004) 1.10
A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody. Nat Clin Pract Neurol (2008) 1.03
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol (2006) 2.93
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin (2013) 2.18
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol (2008) 2.02
Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol (2011) 1.98
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain (2005) 1.58
Seeing injectable MS therapies differently: they are more similar than different. Neurology (2009) 1.47
Chronic cerebrospinal venous insufficiency: have we found the cause and cure of MS? Neurology (2011) 1.42
Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol (2007) 1.31
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol (2013) 1.18
Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought. J Med Internet Res (2013) 1.13
Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol (2013) 1.11
Neurogenesis in the chronic lesions of multiple sclerosis. Brain (2008) 1.10
Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol (2009) 1.07
Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology (2012) 1.07
Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol (2012) 1.00
Web-based self-management for patients with multiple sclerosis: a practical, randomized trial. Telemed J E Health (2011) 0.98
BG-12 in multiple sclerosis. Semin Neurol (2013) 0.90
Translational and clinical science. N Engl J Med (2006) 0.88
Health literacy association with health behaviors and health care utilization in multiple sclerosis: a cross-sectional study. Interact J Med Res (2014) 0.85
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler (2013) 0.83
The effect of plasma exchange on serum anti-JC virus antibodies. Mult Scler (2012) 0.83
Is natalizumab overshooting its rebound? Neurology (2008) 0.81
Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy. Mult Scler (2010) 0.81
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol (2014) 0.81
Primary neuroprotection: the Holy Grail of multiple sclerosis therapy. Neurology (2010) 0.80
Defending eponyms. Arch Neurol (2006) 0.80
Identifying the start of multiple sclerosis injury: a serial DTI study. J Neuroimaging (2014) 0.79
Progressive multiple sclerosis. Curr Opin Neurol (2015) 0.78
Injury to a specific neural pathway detected by ultra-high-field MRI. Neurology (2013) 0.78
A technical approach to dissecting and assessing cadaveric veins pertinent to chronic cerebrospinal venous insufficiency in multiple sclerosis. Neurol Res (2012) 0.78
MRI in multiple sclerosis. Continuum (Minneap Minn) (2010) 0.78
Multiple sclerosis: treating symptoms, and other general medical issues. Cleve Clin J Med (2006) 0.78
Complementary and alternative medicine in multiple sclerosis. Neurology (2014) 0.77
Immunological studies of mitoxantrone in primary progressive MS. J Neuroimmunol (2006) 0.77
Hydration status substantially affects chronic cerebrospinal venous insufficiency assessments. Neurol Clin Pract (2013) 0.77
Picturing injury and recovery with diffusion tensor imaging: the eyes have it. Neurology (2008) 0.76
Disease modifying therapies in multiple sclerosis. Neurology (2002) 0.75
Seeing injectable ms therapies differently: they are more similar than different. Neurology (2010) 0.75
Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis. Int J MS Care (2016) 0.75
Oral BG-12 in multiple sclerosis. N Engl J Med (2013) 0.75
The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology (2002) 0.75
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler (2004) 0.75
Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and reality. Curr Treat Options Cardiovasc Med (2012) 0.75
Author response. Neurology (2014) 0.75
Current treatment options in multiple sclerosis. Curr Treat Options Neurol (2007) 0.75
Pathological mechanisms and disease progression of multiple sclerosis: therapeutic implications. Drugs Today (Barc) (2002) 0.75
Multiple sclerosis treatment: risk mitigation. Continuum (Minneap Minn) (2013) 0.75
Progressive Multiple Sclerosis. Continuum (Minneap Minn) (2016) 0.75